Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their target price on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th.

Minerva Neurosciences Stock Performance

NERV opened at $2.62 on Thursday. The stock has a market cap of $18.32 million, a price-to-earnings ratio of -0.59 and a beta of 0.14. The stock’s 50 day moving average price is $2.71 and its 200-day moving average price is $2.80. Minerva Neurosciences has a one year low of $2.26 and a one year high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). As a group, analysts predict that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.